Opaleye Management’s Blueprint Medicines BPMC Stock Holding History

Opaleye Management’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-100,000	Closed	-$8M	–	47
2019 Q4	$8M	Sell	100,000 -5,000	-5%	-$374K	1.57%	28
2019 Q3	$7.71M	Sell	105,000 -20,000	-16%	-$1.73M	2.79%	15
2019 Q2	$11.8M	Sell	125,000 -5,000	-4%	-$413K	3.59%	9
2019 Q1	$10.4M	Sell	130,000 -170,000	-57%	-$12.6M	2.88%	12
2018 Q4	$16.2M	Hold	300,000	–	–	6.04%	5
2018 Q3	$23.4M	Sell	300,000 -50,000	-14%	-$3.48M	5.96%	5
2018 Q2	$22.2M	Sell	350,000 -250,000	-42%	-$19.9M	5.75%	5
2018 Q1	$55M	Sell	600,000 -135,000	-18%	-$11.6M	15.73%	2
2017 Q4	$55.4M	Hold	735,000	–	–	17.75%	2
2017 Q3	$51.2M	Sell	735,000 -145,000	-16%	-$7.75M	18.11%	1
2017 Q2	$44.6M	Hold	880,000	–	–	18.63%	1
2017 Q1	$35.2M	Hold	880,000	–	–	17.51%	1
2016 Q4	$24.7M	Buy	880,000 +95,000	+12%	+$2.86M	14.54%	1
2016 Q3	$23.3M	Buy	785,000 +535,000	+214%	+$13.3M	12.2%	1
2016 Q2	$5.06M	Buy	250,000 +30,000	+14%	+$545K	3.38%	6
2016 Q1	$3.97M	Sell	220,000 -55,000	-20%	-$954K	2.48%	16
2015 Q4	$7.24M	Buy	275,000 +145,000	+112%	+$3.26M	3.03%	12
2015 Q3	$2.77M	Buy	+130,000	New	+$3.6M	1.37%	29

Other funds holding BPMC

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Opaleye Management's BPMC Position: Q1 2020 in Review

Opaleye Management sold out of Blueprint Medicines (BPMC) in Q1 2020, closing a stake of 100,000 shares — an estimated $8M sold.

Opaleye Management first reported a position in BPMC in Q3 2015 and held it in 18 quarters. The position peaked at $55.4M in Q4 2017. 213 funds tracked by Wall St. Rank hold BPMC as of Q1 2020.

Opaleye Management reported no remaining Blueprint Medicines position as of Q1 2020 after selling out during the quarter.
Opaleye Management sold 100,000 Blueprint Medicines shares in Q1 2020, an estimated $8M.
Opaleye Management first reported a position in Blueprint Medicines in Q3 2015 and held it in 18 quarters.
Opaleye Management's Blueprint Medicines position peaked at $55.4M in Q4 2017.
213 funds tracked by Wall St. Rank held Blueprint Medicines as of Q1 2020.

Based on Opaleye Management's 13F filing for Q1 2020, filed 15 May 2020.